Publications by authors named "MARIO Mandala"

Claim this Profile
N
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
Georgina V Long, Nitya Nair, Daniel Marbach, Richard A Scolyer, Sabine Wilson, Mario Mandala

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis.
Mario Mandalà, Filippo Ugolini, Lorenzo Caldirola, Eliana Rulli, Antonella Manca

Eur J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Sonidegib Cytoreductive Activity in Locally Advanced Basal Cell Carcinoma Treatment: A Delphi Consensus.
Paolo Antonio Ascierto, Maria Concetta Fargnoli, Corrado Caracò, Emi Dika, Mario Mandalà

Int J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
Mario Mandalà, Teresa Amaral, Piotr Rutkowski, Maria Chiara Sergi, Marie-Lena Rasch

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF or BRAF mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.
Caroline Robert, Michal Kicinski, Caroline Dutriaux, Émilie Routier, Anne-Sophie Govaerts

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrochemotherapy for Cancers Affecting the Skin: Ten Years of Experience in a Tertiary Referral Hospital.
Piero Covarelli, Carlo Boselli, Francesco Barberini, Matteo Matteucci, Georgi Popivanov

Ann Ital Chir· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical validation of droplet digital PCR assays in detecting BRAF-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
Mahrukh M Syeda, Georgina V Long, James Garrett, Victoria Atkinson, Mario Santinami, Mario Mandala

Lancet Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study.
Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina

Future Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results" [Eur J Cancer 213 (2024):115079].
Alice Indini, Fabio Didoné, Daniela Massi, Susana Puig, Jordi Rubio Casadevall

Eur J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma.
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance

Future Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Mario Mandala

Eur J Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Mario Mandala

Eur J Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study.
Michael Weller, Emilie Le Rhun, Lydia Tsamtsouri, Reinhard Dummer, Matthias Guckenberger, Mario Mandala

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.
Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results.
Alice Indini, Fabio Didoné, Daniela Massi, Susana Puig, Jordi Rubio Casadevall

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Georgina V Long, Axel Hauschild, Mario Santinami, John M Kirkwood, Victoria Atkinson, Mario Mandala

N Engl J Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study).
Mario Mandalà, Andrea Ferrari, Ines B Brecht, Karijn Pm Suijkerbuijk, Linda Maschke

Eur J Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, Georgina V Long

Eur J Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Paolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski

NEJM Evid· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating cancer-associated venous thromboembolism: A practical approach.
Eric Van Cutsem, Isabelle Mahé, Enriqueta Felip, Giancarlo Agnelli, Ahmad Awada, Mario Mandala

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Emanuel Bührer, Michal Kicinski, Mario Mandala, Madeline Pe, Georgina V Long

Lancet Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins to prevent anthracycline-related myocardial toxicity: The jury is still out.
Mario Mandalà, Claudia Bartolini, Cecilia Becattini

Eur J Intern Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance

Eur J Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D d'Arienzo, Florentia Mina, Mario Mandala

EClinicalMedicine· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis